MS Pharma Takes MENA Rights To Lucentis Rival
Company Will Register And Market Bioeq-Formycon FYB201 Ranibizumab Candidate
MS Pharma has struck a deal with Bioeq to gain rights in the MENA region to its FYB201 proposed biosimilar ranibizumab rival to Lucentis, developed in collaboration with Formycon.
